GAPNA is a name chosen to reflect the diversity of our current and potential members, all who are interested in providing the highest quality of care to older adults.
We are the only advanced practice nursing organization that focuses on older adults, the fastest growing segment of the population.
If you would like to discuss your involvement and more details, please contact Jack Edelman, Director of Marketing, at 856-256-2313, Jack.Edelman@ajj.com or Heidi Perret, Marketing Coordinator, at 856-256-2375, firstname.lastname@example.org.
GAPNA thanks our current Strategic Partners for their support of our organization.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders.
3611 Valley Centre Drive, Suite 300
San Diego, CA 92130
Avanir Pharmaceuticals is a pharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.
30 Enterprise, Suite 400
Aliso Viejo, CA 92656
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.
The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia and uterine fibroids*.
Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie).
Neurocrine Biosciences, Inc.
12780 El Camino Real
San Diego, CA 92130
For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, Co., Ltd., is focused on developing and commercializing treatments for disorders of the central nervous system (CNS). Both are a part of the global conglomerate SK Group, the second largest company in Korea. SK life science is located in Paramus, New Jersey.
We have a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, Lennox‐Gastaux syndrome and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize independently is cenobamate (YKP3089), an investigational compound for the potential treatment of partial‐onset seizures in adult patients.
For more information, visit their websites listed below.